Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1018 EUR | -.--% | +0.20% | -32.81% |
Business Summary
AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Oncology Products
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Rest of the World
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 31/05/21 |
Ashish Gulati
CTO | Chief Tech/Sci/R&D Officer | - | - |
Julien Miara
BRD | Director/Board Member | - | 16/09/20 |
Valérie Leroy
IRC | Investor Relations Contact | - | 30/11/16 |
Hui Ping Jiang
LAW | General Counsel | - | - |
Human Resources Officer | - | 09/02/15 | |
Philippe Maitre
PRN | Corporate Officer/Principal | 68 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Mallet
BRD | Director/Board Member | 64 | 13/10/21 |
Khalil Barrage
BRD | Director/Board Member | 59 | - |
Director/Board Member | 61 | 28/06/11 | |
Julien Miara
BRD | Director/Board Member | - | 16/09/20 |
Bryan Giraudo
BRD | Director/Board Member | 48 | 22/11/21 |
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 31/05/21 |
Robert L Coleman
BRD | Director/Board Member | - | 13/10/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,364,273 | 114,123,888 ( 73.93 %) | 368,174 ( 0.2385 %) | 73.93 % |
Company contact information
Valerio Therapeutics SA
49, blvd. du Général Martial Valin
75015, Paris
+33 1 70 38 33 99
http://www.onxeo.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- ALVIO Stock
- C4X Stock
- Company Valerio Therapeutics